Track topics on Twitter Track topics that are important to you
Takeda Pharmaceutical has agreed to sell two of its non-core drugs in deals that could generate up to $5.7 billion for the pharma giant—and are intended to refocus its portfolio on five key business areas following its recently-completed $59.8 billion purchase of Shire. Takeda said it will sell its dry eye disease treatment Xiidra® (lifitegrast […]NEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...